ArticleBMC urology2025
Survey of perioperative treatment in muscle-invasive bladder cancer using Japanese hospital-based claims database.
Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Perioperative Systemic Treatment Patterns and Postoperative Mortality Among Patients With Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy in Japan: WAKKA-MIBC Study.International journal of urology : official journal of the Japanese Urological Association · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeUrothelial carcinoma (UC) is a common malignant tumor of the urinary tract, with bladder cancer as the most frequent type. Radical cystectomy (RC) is the standard treatment for muscle-invasive bladder cancer (MIBC), and perioperative chemotherapy is recommended in addition to RC in guidelines. However, no established evidence defines the optimal regimen and number of cycles, and treatment varies by institution. Therefore, this study aimed to clarify perioperative treatment patterns for MIBC using a hospital-based claims database.
methodsPatients with claims records for bladder cancer recorded during the case-identification window (2012–2020) were identified using the Medical Data Vision Co., Ltd. database. The database spans April 2008 to July 2021, enabling longitudinal assessment. Patient characteristics and prescribed perioperative chemotherapy regimens were analyzed. Factors associated with neoadjuvant chemotherapy (NAC) were examined using univariable analysis and an exploratory multivariable logistic regression model.
resultsAmong 6,723 patients, 78.5% were men, with a median diagnosis age of 71 years. The treatment groups included 2,324 patients who received NAC, 598 who received adjuvant chemotherapy (AC), 364 who received NAC and AC, and 3,437 who underwent RC-only. NAC utilization rate increased over time (P for trend < 0.0001). Gemcitabine plus cisplatin was the most frequently administered regimen. Univariable analysis revealed an association between clinical stage 3 or higher and the NAC administration. In contrast, older age and comorbidities were associated with non-administration of NAC. Furthermore, the hospital size and cancer hospital designation influenced NAC administration.
conclusionPerioperative chemotherapy utilization for MIBC has increased annually. Patient characteristics and treatment facility factors influence NAC administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.